CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Adrian Jubb, MB ChB, PhD, FRCPath, as Chief Medical Officer. Dr. Jubb joins the Flare leadership team at a key inflection point as the company progresses from early drug discovery into clinical development.
“We are extremely fortunate to be growing Flare’s executive team with the addition of Adrian, who is vastly accomplished and brings a wealth of oncology clinical development experience,” said Abbie Celniker, PhD, interim Chief Executive Officer of Flare and partner at Third Rock Ventures. “Adrian’s leadership and deep drug development expertise will be invaluable as we enter our next phase of growth, advancing precision oncology programs from our drug discovery engine into the clinic.”
Dr. Adrian Jubb is a board-certified physician scientist with more than 20 years of research and clinical development experience spanning oncology, infectious disease and neuroscience. Dr. Jubb has devoted much of his career to the translational and clinical development of cancer medicines, including Avastin®, Tarceva®, Zelboraf®, and Cotellic®, as well as multiple investigational agents, including MetMAb, Apo2L, anti-LILRB4, anti-CD96 and anti-CD200R1. Most recently, Dr. Jubb served as Head of Clinical Oncology and Neurology at 23andMe, where he led teams accountable for the IND filings and first-in-human clinical trials for two immune-oncology checkpoint inhibitors. Prior to 23andMe, Dr. Jubb held roles as Chief Medical Officer of Immune-Onc Therapeutics, Vice President and Head of Early Development at Achaogen and Medical Director in Oncology at Genentech. He holds MB ChB (Hons), PhD, and BSc (Hons) degrees from the University of Leeds (UK) and is a Fellow of the Royal College of Pathologists in London.
“Flare’s approach to finding and drugging transcription factors may elucidate previously unexplored and meaningful treatment possibilities for cancer patients,” said Dr. Jubb. “In just one year of discovery, the Flare team has made remarkable progress identifying genetically defined targets and promising chemical matter to develop new therapeutic candidates. I am both honored and excited to join the talented team at Flare as they continue to build a portfolio and bring potentially transformative programs into the clinic.”
About Flare Therapeutics
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery efforts to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology and inflammation. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management. For more information, please visit www.flaretx.com.
